Unknown

Dataset Information

0

Tumor Treating Fields in the Management of Patients with Malignant Gliomas.


ABSTRACT: OPINION STATEMENT:Malignant gliomas remain a challenging cancer to treat due to limitations in both therapeutic and efficacious options. Tumor treating fields (TTFields) have emerged as a novel, locoregional, antineoplastic treatment modality with favorable efficacy and safety being demonstrated in the most aggressive type of malignant gliomas, glioblastoma (GBM). In 2 large randomized, controlled phase 3 trials, the addition of TTFields was associated with increased overall survival when combined with adjuvant temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM (ndGBM) and comparable overall survival compared with standard chemotherapy in patients with recurrent GBM (rGBM). TTFields target cancer cells by several mechanisms of action (MoA) including suppression of proliferation, migration and invasion, disruption of DNA repair and angiogenesis, antimitotic effects, and induction of apoptosis and immunogenic cell death. Having several MoAs makes TTFields an attractive modality to combine with standard, salvage, and novel treatment regimens (e.g., radiotherapy, chemotherapy, and immunotherapy). Treatment within the field of malignant gliomas is evolving to emphasize combinatorial approaches that work synergistically to improve patient outcomes. Here, we review the current use of TTFields in GBM, discuss MOA and treatment delivery, and consider the potential for its wider adoption in other gliomas.

SUBMITTER: Ghiaseddin AP 

PROVIDER: S-EPMC7391234 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6366009 | BioStudies
2016-01-01 | S-EPMC5035531 | BioStudies
| S-ECPF-GEOD-61710 | BioStudies
2014-09-26 | E-GEOD-61710 | BioStudies
2014-09-26 | E-GEOD-61710 | ArrayExpress
2017-01-01 | S-EPMC6009218 | BioStudies
2018-01-01 | S-EPMC6144088 | BioStudies
2020-01-01 | S-EPMC7641478 | BioStudies
2015-01-01 | S-EPMC5528820 | BioStudies
1000-01-01 | S-EPMC5386539 | BioStudies